|
Market Closed -
NYSE
23:00:02 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 229.94 USD | -9.05% |
|
-9.06% | -4.54% |
| 10-30 | RBC Raises Price Target on ResMed to $288 From $262, Keeps Outperform Rating | MT |
| 10-30 | Citigroup Adjusts Price Target on ResMed to $270 From $240 | MT |
Company Valuation: ResMed, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 30,691 | 32,133 | 28,117 | 37,762 | 28,145 | 32,339 | - | - |
| Change | - | 4.7% | -12.5% | 34.31% | -25.47% | 14.9% | - | - |
| Enterprise Value (EV) 1 | 31,192 | 33,346 | 28,585 | 37,221 | 27,335 | 31,337 | 30,783 | 30,194 |
| Change | - | 6.9% | -14.28% | 30.21% | -26.56% | 14.64% | -1.77% | -1.91% |
| P/E | 39.6x | 35.9x | 27.7x | 27.1x | 18.7x | 19.8x | 17.9x | 16.2x |
| PBR | 9.35x | 7.76x | 5.78x | 6.33x | 4.27x | 4.66x | 4.15x | 4.09x |
| PEG | - | 2.4x | 2x | 0.7x | 1.93x | 1.7x | 1.8x | 1.5x |
| Capitalization / Revenue | 8.58x | 7.61x | 6x | 7.34x | 4.98x | 5.54x | 5.21x | 4.93x |
| EV / Revenue | 8.72x | 7.9x | 6.1x | 7.23x | 4.84x | 5.37x | 4.96x | 4.61x |
| EV / EBITDA | 26.8x | 25.3x | 18.1x | 19.8x | 11.7x | 13.9x | 12.7x | 11.7x |
| EV / EBIT | 31.2x | 27.2x | 19.3x | 21.1x | 13.4x | 15x | 13.6x | 12.5x |
| EV / FCF | 144x | 58.1x | 22x | 22.4x | 16.6x | 18.9x | 17.3x | 15.9x |
| FCF Yield | 0.69% | 1.72% | 4.55% | 4.46% | 6.03% | 5.28% | 5.77% | 6.28% |
| Dividend per Share 2 | 1.68 | 1.8 | 1.92 | 2.12 | 2.46 | 2.673 | 2.916 | 3.162 |
| Rate of return | 0.8% | 0.82% | 1% | 0.82% | 1.26% | 1.16% | 1.27% | 1.38% |
| EPS 2 | 5.3 | 6.09 | 6.92 | 9.51 | 10.43 | 11.64 | 12.83 | 14.19 |
| Distribution rate | 31.7% | 29.6% | 27.7% | 22.3% | 23.6% | 23% | 22.7% | 22.3% |
| Net sales 1 | 3,578 | 4,223 | 4,685 | 5,146 | 5,653 | 5,834 | 6,208 | 6,556 |
| EBITDA 1 | 1,162 | 1,317 | 1,576 | 1,884 | 2,329 | 2,252 | 2,419 | 2,578 |
| EBIT 1 | 1,000 | 1,224 | 1,478 | 1,763 | 2,039 | 2,089 | 2,259 | 2,418 |
| Net income 1 | 779.4 | 897.6 | 1,021 | 1,401 | 1,523 | 1,640 | 1,781 | 1,909 |
| Net Debt 1 | 501.5 | 1,213 | 468.9 | -541.2 | -809.9 | -1,002 | -1,556 | -2,144 |
| Reference price 2 | 209.63 | 218.50 | 191.42 | 258.00 | 194.88 | 229.94 | 229.94 | 229.94 |
| Nbr of stocks (in thousands) | 146,405 | 147,062 | 146,884 | 146,365 | 144,421 | 140,639 | - | - |
| Announcement Date | 8/11/22 A | 8/3/23 A | 8/1/24 A | 7/31/25 A | 8/6/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.75x | 5.37x | 13.92x | 1.16% | 32.34B | |
| 35.69x | 6.07x | 23.2x | 0.27% | 258B | |
| 36.92x | 7x | 21.93x | 0.62% | 163B | |
| 49.76x | 12.05x | 25.86x | -.--% | 150B | |
| 17x | 3.45x | 11.22x | -.--% | 60.84B | |
| 36.47x | 7.31x | 23.11x | -.--% | 53.03B | |
| 21x | 2.51x | 12.66x | 2.4% | 53.31B | |
| 34.07x | 6.75x | 22.92x | 0.59% | 49.3B | |
| 47.92x | 11.82x | 26.05x | -.--% | 50.67B | |
| 81x | 7.7x | 23.37x | -.--% | 45.46B | |
| Average | 37.96x | 7.00x | 20.42x | 0.5% | 91.58B | |
| Weighted average by Cap. | 38.44x | 7.32x | 21.82x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RMD Stock
- Valuation ResMed, Inc.
Select your edition
All financial news and data tailored to specific country editions
